Nigeria: Ranbaxy Tackles Malaria With Novel Drug-Synriam
Just 3 tablets, Taken one daily for three days. Available at major pharmacies across Nigeria Indian registered pharmaceutical company in Nigeria, Ranbaxy Laboratories, has promised to kick out malaria in Nigeria with its first ever New Chemical Entity (NCE), which according to the CEO and Managing Director of the company, Mr. Arun Sawhney, would address the existing challenges of resistance to available drugs, price fluctuations, supply constraints and high pill burden". Arun told Vanguard that the India's first NCE, Synriam™ (arterolane maleate 150 mg + piperaquine phosphate 75 mg drug) conforms to the recommendations of the World Health Organization (WHO) for using combination therapy in malaria. Synriam™ provides quick relief from most malaria-related symptoms, including fever, and has a high cure rate of over 95 per cent, "Most malaria cases and deaths occur in sub-Saharan Africa. It is the need of the hour to make available new therapy options to pat...